Key markers of ferroptosis

DOI: https://doi.org/10.29296/24999490-2024-04-03

M.D. Tokhtueva(1), V.V. Melekhin(1, 2)
1-Federal State Autonomous Educational Institution of Higher Education “Ural Federal University named after the first
President of Russia B.N. Yeltsin” of the Ministry of Science and Higher Education of the Russian Federation,
Mira str., 19, Yekaterinburg, 620002, Russian Federation;
2-Federal State Budgetary Educational Institution of Higher Education
“Ural Federal State Medical University”, Healthcare Ministry of Russia, Repina str.,
3, Yekaterinburg, 620028, Russian Federation

Introduction. Ferroptosis is a type of programmed cell death associated with excessive accumulation of endogenous iron in the cell, accompanied by the production of reactive oxygen species and, as a result, lipid peroxidation. The literature review examines the key markers of ferroptosis, which is one of the types of programmed cell death other than apoptosis, necroptosis, pyroptosis, etc. Purpose: to collect and process information on the main markers of ferroptosis, which will allow to adapt and optimize the processes of its study. Material and methods: analysis of literary sources of domestic and foreign origin on a given topic. Results: articles have been found and analyzed, including those from the last 5 years, confirming the prospects of ferroptosis as a potential pharmacological target. Conclusion. Understanding the main signs of the launch of this process is an integral part of the research work aimed at finding new therapeutic targets associated with the launch of ferroptosis, which, in turn, represents a promising pharmacological model, since It has a high potential for the future treatment of drug-resistant types of pathologies.
Keywords: 
ferroptosis, programmed cell death, markers of ferroptosis
Список литературы: 
  1. Stockwell B.R., Jiang X., Gu W. Emerging mechanisms and disease relevance of ferroptosis. Trends in cell biology. 2020; 30 (6): 478–90. DOI: 10.1016/j.tcb.2020.02.009.
  2. Kerr J.F.R., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. British journal of cancer. 1972; 26 (4): 239–57. DOI: 10.1038/bjc.1972.33.
  3. Wang Y., Kanneganti T.D. From pyroptosis, apoptosis and necroptosis to PANoptosis: A mechanistic compendium of programmed cell death pathways. Computational and structural biotechnology journal. 2021; 19: 4641–57. DOI: 10.1016/j.csbj.2021.07.038.
  4. Потапнев М.П. Аутофагия, апоптоз, некроз клеток и иммунное распознавание своего и чужого. Иммунология. 2014; 35 (2): 95–102. [Potapnev M.P. Autophagy, apoptosis, cell necrosis and immune recognition of one’s own and another’s. Immunology. 2014; 35 (2): 95–102 (in Russian)]
  5. Hickman J.A. Apoptosis and chemotherapy resistance. European J. of Cancer. 1996; 32 (6): 921–6. DOI: 10.1016/0959-8049(96)00080-9.
  6. Meirow D., Biederman H., Anderson R.A., Wallace W.H. B. Toxicity of chemotherapy and radiation on female reproduction. Clinical obstetrics and gynecology. 2010; 53 (4): 727–39. DOI: 10.1097/GRF.0b013e3181f96b54.
  7. Rybak L.P., Mukherjea D., Ramkumar V. Mechanisms of Cisplatin-Induced Ototoxicity and Prevention. Debashree MukherjeaVickram Ramkumar. Seminars in Hearing. 2019; 40 (2): 197–204. DOI: 10.1055/s-0039-1684048.
  8. Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., Morrison III B., Stockwell B.R. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149 (5): 1060–72. DOI: 10.1016/j.cell.2012.03.042.
  9. Du Y., Guo Z. Recent progress in ferroptosis: inducers and inhibitors. Cell Death Discovery. 2022; 8 (1): 501. DOI: 10.1038/s41420-022-01297-7.
  10. Чубенко В.А. МетаболизМ железа и ферроптоз как терапевтическая Мишень. Практическая онкология. 2022; 23 (3): 127–32. DOI: 10.31917/2303127 [Chubenko V.A. Iron metabolism and ferroptosis as a therapeutic Target. Practical oncology. 2022; 23 (3): 127–32. DOI: 10.31917/2303127 (in Russian)].
  11. Jiang X., Stockwell B.R., Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nature reviews Molecular cell biology. 2021; 22 (4): 266–82. DOI: 10.1038/s41580-020-00324-8.
  12. Dolma S., Lessnick S.L., Hahn W.C., Stockwell B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer cell. 2003; 3 (3): 285–96. DOI: 10.1016/s1535-6108(03)00050-3.
  13. Yang W.S., Stockwell B.R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chemistry & biology. 2008; 15 (3): 234–45. DOI: 10.1016/j.chembiol.2008.02.010.
  14. Li J., Cao F., Yin. H.L., Huang Z.J., Lin. Z.T., Mao N., Sun B., Wang G. Ferroptosis: past, present and future. Cell death & disease. 2020; 11 (2): 88. DOI: 10.1038/s41419-020-2298-2.
  15. Lee S., Hwang N., Seok B.G., Lee S., Lee S.J., Chung S.W. Autophagy mediates an amplification loop during ferroptosis. Cell Death & Disease. 2023; 14 (7): 464. DOI: 10.1038/s41419-023-05978-8.
  16. Battaglia A.M., Chirillo R., Aversa I., Sacco A., Costanzo F., Biamonte F. Ferroptosis and cancer: mitochondria meet the “iron maiden” cell death. Cells. 2020; 9 (6): 1505. DOI: 10.3390/cells9061505.
  17. Вартанян А.А. Метаболизм железа, ферроптоз, рак. Российский биотерапевтический журнал. 2017; 16 (3): 14–20. DOI: 10.17650/1726-9784-2017-16-3-14-20. [Vartanian A.A. Iron metabolism, ferroptosis and cancer. Russian Journal of Biotherapy. 2017; 16 (3): 14–20. DOI: 10.17650/1726-9784-2017-16-3-14-20 (in Russian)].
  18. Shah R., Shchepinov M.S., Pratt D.A. Resolving the role of lipoxygenases in the initiation and execution of ferroptosis. ACS central science. 2018; 4 (3): 387–96. DOI:10.1021/acscentsci.7b00589.
  19. Haeggstrom J.Z., Funk C.D. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chemical reviews. 2011; 111 (10): 5866–98. DOI: 10.1021/cr200246d.
  20. Zou Y., Li. H., Graham E.T., Deik A.A., Eaton J.K., Wang W., Sandoval-Gomez G., Clish C.B., Doench J.G., Schreiber S.L. Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nature chemical biology. 2020; 16 (3): 302–9. DOI: 10.1038/s41589-020-0472-6.
  21. Zhang H.L., Hu B.X., Li Z.L., Du T., Shan J.L., Ye Z.P., Peng X.D., Li X., Huang Y., Zhu X.Y., Chen Y.H., Feng G.K., Yang D., Deng R., Zhu X.F. PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis. Nature cell biology. 2022; 24 (1): 88–98. DOI: 10.1038/s41556-021-00818-3.
  22. Новиков В.Е., Левченкова О.С., Пожилова Е.В. Роль активных форм кислорода в физиологии и патологии клетки и их фармакологическая регуляция. Обзоры по клинической фармакологии и лекарственной терапии. 2014; 12 (4): 13–21. DOI: 10.17816/RCF12413-21. [Novikov V.E., Levchenkova O.S., Pozhilova E. The role of reactive oxygen species in cell physiology and pathology and their pharmacological regulation. Reviews of clinical pharmacology and drug therapy. 2014; 12 (4): 13–21. DOI: 10.17816/RCF12413-21. (in Russian)].
  23. Prasad A., Pospíšil P., Tada M. Reactive oxygen species (ROS) detection methods in biological system. Frontiers in physiology. 2019; 1316.
  24. Chen X., Comish P.B., Tang D., Kang R. Characteristics and biomarkers of ferroptosis. Frontiers in cell and developmental biology. 2021; 9: 637162. DOI: 10.3389/fphys.2019.01316.
  25. Xie Y., Hou W., Yu Y., Huang J., Sun X., Kang R., Tang D. Ferroptosis: process and function. Cell Death & Differentiation. 2016; 23 (3): 369–79. DOI: 10.1038/cdd.2015.158.
  26. Feng H., Schorpp K., Jin J., Yozwiak C.E., Hoffstrom B.G., Decker A.M., Rajbhandari P., Stokes M.E., Bender H.G., Csuka J.M., Upadhyayula P.S., Canoll P., Uchida. K., Soni R.K., Hadian K., Stockwell B.R. Transferrin Receptor Is a Specific Ferroptosis Marker. Cell Reports. 2020; 30 (10): 3411–23. DOI: 10.1016/j.celrep.2020.02.049.
  27. Sun X., Ou Z., Xie M., Kang R., Fan Y., Niu X., Wang H., Cao L., Tang D. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene. 2015; 34 (45): 5617–25. DOI: 10.1038/onc.2015.32.
  28. Hou K., Liu L., Fang Z.H., Zong W.X., Sun D., Gue Z., Cao. L. The role of ferroptosis in cardio-oncology. Archives of Toxicology. 2024; 98 (3): 1–26. DOI: 10.1007/s00204-023-03665-3.
  29. Kagan V.E., Mao G., Qu F., Angeli J.P., Doll S., Croix C.S., Dar H.H., Liu B., Tyurin V.A. Ritov V.B., Kapralov A.A., Amoscato A.A., Jiang J., Anthonymuthu T., Mohammadyani D., Yang O., Proneth B., Klein-Seetharaman J., Watkins S., Bahar I., Greenberger J., Mallampalli R.K., Stockwell B.R., Tyurina Y.Y., Conrad M., Bayir H. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nature Chemical Biology. 2017; 13 (1): 81–90. DOI: 10.1038/nchembio.2238.
  30. Lyamzaev K.G., Panteleeva A.A., Simonyan R.A., Avetisyan A.A., Chernyak B. V. Mitochondrial Lipid Peroxidation Is Responsible for Ferroptosis. Cells. 2023; 12 (4): 611. DOI: 10.3390/cells12040611.
  31. Von Krusenstiern A.N., Robson R.N., Qian N., Qiu B., Hu F., Reznik E., Smith N., Zandkarimi F., Estes V.M., Dupont M., Hirschhorn T., Shchepinov M.S., Min W., Woerpel K.A., Stockwell B.R. Identification of essential sites of lipid peroxidation in ferroptosis. Nature Chemical Biology. 2023; 19 (6): 1–12. DOI: 10.1038/s41589-022-01249-3.
  32. Liu Y., Lu S., Wu L.L., Yang L., Yang L., Wang J. The diversified role of mitochondria in ferroptosis in cancer. Cell Death & Disease. 2023; 14 (8): 519. DOI: 10.1038/s41419-023-06045-y.
  33. Ma T., Du J., Zhang Y., Wang Y., Wang B., Zhang T. GPX4-independent ferroptosis – a new strategy in disease’s therapy. Cell death discovery. 2022; 8 (1): 434. DOI: 10.1038/s41420-022-01212-0.
  34. Wu Y., Shi H., Zheng J., Yang. Y., Lei X., Qian X., Zhu J. Overexpression of FSP1 Ameliorates ferroptosis via PI3K/AKT/GSK3β pathway in PC12 cells with Oxygen-Glucose Deprivation/Reoxygenation. Heliyon. 2023; 9 (8): e18449. DOI: 10.1016/j.heliyon.
  35. Зенков Н.К., Колпаков А.Р., Меньщикова Е.Б. Редокс-чувствительная система Keap1/NRF2/ARE как фармакологическая мишень при сердечно-сосудистой патологии. Сибирский научный медицинский журнал. 2015; 35 (5): 5–25. [Zenkov N.K., Kolpakov A.R., Men’shhikova E.B. The redox-sensitive Keap1/NRF2/ARE system as a pharmacological target in cardiovascular pathology. Siberian Scientific Medical J. 2015; 35 (5): 5–25 (in Russian)].
  36. Song X., Long D. NRF2 and ferroptosis: a new research direction for neurodegenerative diseases. Frontiers in neuroscience. 2020; 14: 267. DOI: 10.3389/fnins.2020.00267.
  37. Chang L.C., Chiang S.K., Chen S.E., Yu Y.L., Chou R.H., Chang W. C. Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. Cancer Lett. 2018; 416: 124–37. DOI: 10.1016/j.canlet.2017.12.025.
  38. Dodson M., Castro-Portuguez R., Zhang D.D. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox biology. 2019; 23: 101107. DOI: 10.1016/j.redox.2019.101107.
  39. Anandhan A. Dodson M., Shakya A. , Chen J., Liu P., Wei Y., Tan H., Wang Q., Jiang Z., Yang K., Garcia J.G., Chambers S.K., Chapman E., Ooi A., Yang-Hartwich Y., Stockwell B.R., Zhang D.D. NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8. Science Advances. 2023; 9 (5): eade9585. DOI: 10.1126/sciadv.ade9585.
  40. Jin Y., Qiu J., Lu X., Li G. C-MYC inhibited ferroptosis and promoted immune evasion in ovarian cancer cells through NCOA4 mediated ferritin autophagy. Cells. 2022; 11 (24): 4127. DOI: 10.3390/cells11244127.
  41. Liu Y., Gu W. p53 in ferroptosis regulation: the new weapon for the old guardian. Cell Death & Differentiation. 2022; 29 (5): 895–910. DOI: 10.1038/s41418-022-00943-y.
  42. Mishima E., Nakamura T., Zheng J., Zhang W., Dias Mourão A. S., Sennhenn P., Conrad M. DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition. Nature. 2023; 619 (7968): 9–18. DOI: 10.1038/s41586-023-06269-0.
  43. Yi J., Zhu J., Wu J., Thompson C. B., Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proceedings of the National Academy of Sciences. 2020; 117 (49): 31189–97. DOI: 10.1073/pnas.2017152117.
  44. Wang Z., Li M., Liu Y., Qiao Z., Bai T., Yang L., Liu B. Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression. Oncology reports. 2021; 46 (5): 240. DOI: 10.3892/or.2021.8191.
  45. Ding K., Liu C., Li. L., Yang M., Jiang N., Luo S., Sun L. Acyl-CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism. Chinese Medical J. 2023; 136 (21): 2521–37. DOI: 10.1097/CM9.0000000000002533.
  46. Ding Y., Chen X., Liu C., Ge W., Wang Q., Hao X., Wang M., Chen Y., Zhang Q. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells. Journal of hematology & oncology. 2021; 14 (1): 1–21. DOI: 10.1186/s13045-020-01016-8.
  47. Tsuji Y. Transmembrane protein western blotting: Impact of sample preparation on detection of SLC11A2 (DMT1) and SLC40A1 (ferroportin). PLoS One. 2020; 15 (7): e0235563. DOI: 10.1371/journal.pone.0235563.
  48. Dong H., Xia Y., Jin S., Xue C., Wang Y., Hu R., Jiang H. Nrf2 attenuates ferroptosis-mediated IIR-ALI by modulating TERT and SLC7A11. Cell death & disease. 2021; 12 (11): 1027. DOI: 10.1038/s41419-021-04307-1.
  49. Jiang L., Kon N., Li T., Wang S.J., Su T., Hibshoosh H., Baer R., Gu W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015; 520 (7545): 57–62. DOI: 10.1038/nature14344.
  50. Hu Q., Wei W., Wu D., Huang F., Li M., Li W., Yin J., Peng Y., Lu Y., Zhao Q., Liu L. Blockade of GCH1/BH4 axis activates ferritinophagy to mitigate the resistance of colorectal cancer to erastin-induced ferroptosis. Frontiers in cell and developmental biology. 2022; 10: 810327. DOI: 10.3389/fcell.2022.810327.